The latest update is out from Brainstorm Cell Therapeutics (BCLI).
Brainstorm Cell Therapeutics Inc. has announced the appointment of Dr. Hartounian as Executive Vice President and Chief Operating Officer, starting June 24, 2024. With a robust background, including leading BioCentriq to a successful acquisition and holding various CEO positions, Dr. Hartounian brings valuable experience to the role. His compensation includes a $450,000 base salary, stock options, and eligibility for bonuses and comprehensive benefits. The terms of his employment ensure long-term commitment, with stock vesting tied to continued employment and severance provisions in place for termination scenarios.
Find detailed analytics on BCLI stock on TipRanks’ Stock Analysis page.
